In May 2026, one of the most common hormonal conditions affecting women of reproductive age was officially given a new name. Polycystic ovary syndrome — PCOS — is now polyendocrine metabolic ovarian syndrome, or PMOS. The change was announced at the European Congress of Endocrinology and published in The Lancet, the result of a 14-year global consensus process involving 56 academic and patient organisations across six continents.

For patients currently navigating fertility treatment in the UK, the name change raises immediate questions. Does it change how you are diagnosed? Does it affect NHS eligibility? What does it mean for your IVF protocol?

This article answers those questions directly.

Why Was the Name Changed?

The original name — polycystic ovary syndrome — was coined in 1935, based on the observation that some women had enlarged ovaries with multiple fluid-filled follicles. The name has caused clinical problems ever since.

The name is inaccurate in two ways:

First, the "cysts" it refers to are not pathological cysts — they are underdeveloped follicles that failed to ovulate. Many patients have spent years believing they have ovarian cysts, when they do not.

Second, and more significantly, the name places the ovary at the centre of a condition that is primarily about systemic hormonal and metabolic dysregulation. Research has consistently shown that PCOS/PMOS is a multisystem condition involving insulin resistance, androgen excess, disrupted metabolism, and effects on cardiovascular health, mental health, and skin — not just the ovaries.

The new name — polyendocrine metabolic ovarian syndrome (PMOS) — reflects this. "Polyendocrine" acknowledges the multiple hormonal systems involved. "Metabolic" acknowledges the central role of insulin resistance and metabolic dysfunction. "Ovarian" is retained to preserve the reproductive dimension, but is no longer the lead descriptor.

The consensus involved responses from over 14,000 clinicians and patients globally. The renaming process is described in full in the Lancet paper.

What Changes for UK Patients Right Now?

The short answer: the clinical reality changes more than the paperwork — for now.

The formal transition period is three years (to approximately 2028), during which journals, textbooks, guidelines, and disease classifications will progressively update. In practice, NHS documentation, GP systems, and clinic referral letters will continue to use "PCOS" for some time. You may see both terms in use during this period.

What does change — and what the renaming is specifically intended to shift — is clinical approach:

1. Metabolic screening should now be standard, not optional. Under the PCOS framing, many patients were assessed primarily for ovarian function and fertility. The PMOS framework explicitly requires that insulin resistance, blood glucose regulation, lipid profiles, and cardiovascular risk factors be assessed as part of routine care — not just when a patient presents with obvious metabolic symptoms.

If you have been diagnosed with PCOS and have never been tested for insulin resistance or glucose tolerance, this is now a gap in your care that you can explicitly raise with your GP or fertility consultant.

2. The condition is no longer primarily a gynaecological problem. The PMOS framework positions the condition as an endocrinological and metabolic disorder with reproductive consequences — not a reproductive disorder that happens to have metabolic effects. This distinction matters for which specialist you see and what investigations are done.

3. Fertility is not the defining issue. A recurring problem with the PCOS label was that patients without immediate fertility goals were often told — sometimes explicitly — that treatment was unnecessary until they wanted to conceive. The PMOS framework is explicit that metabolic and endocrine management is warranted regardless of reproductive intent.

Insulin Resistance and IVF: Why It Matters

Insulin resistance is now understood to be central to PMOS — present in the majority of patients regardless of body weight. Its relevance to IVF is direct:

Stimulation response. Insulin resistance affects how the body responds to FSH stimulation. Patients with significant insulin resistance may respond unpredictably to standard protocols, and OHSS risk (ovarian hyperstimulation syndrome) may be elevated. The antagonist protocol with careful monitoring is typically preferred for PMOS patients.

Egg and embryo quality. Chronically elevated insulin and androgen levels create a suboptimal follicular environment. Improving insulin sensitivity — through lifestyle changes, metformin, or inositol — before starting IVF may improve egg quality and fertilisation rates.

Endometrial receptivity. Metabolic dysregulation can affect implantation. Some evidence suggests that treating insulin resistance improves endometrial environment and IVF outcomes, though the data is still developing.

Miscarriage risk. PMOS patients have an elevated early pregnancy loss rate, partly attributed to metabolic and hormonal factors. Optimising metabolic status before transfer — and monitoring closely after — is increasingly standard practice.

If you are starting IVF with a PMOS diagnosis, asking your consultant specifically about insulin resistance testing and whether metformin or inositol supplementation is appropriate for your case is a reasonable and evidence-informed question. See PCOS and IVF in the UK for more on protocol considerations.

Does the Name Change Affect NHS IVF Eligibility?

Not directly, and not immediately.

NHS IVF eligibility is set by each Integrated Care Board (ICB) based on clinical criteria — most commonly AMH, BMI, age, number of previous children, and relationship status. PCOS/PMOS as a diagnosis is relevant in that it is a recognised cause of ovulatory infertility, which is one pathway to NHS referral.

The diagnostic criteria for PMOS remain the same as for PCOS — satisfying two of three criteria (oligo/anovulation, hyperandrogenaemia, and polycystic ovarian morphology on ultrasound). The name changes; the diagnostic threshold does not.

What may change over time is the pathway to diagnosis. The PMOS framework's emphasis on metabolic assessment may mean that more patients are correctly identified — particularly those who were previously dismissed because their ultrasound did not show "classic" polycystic morphology. Approximately 70% of PMOS patients are currently estimated to be undiagnosed globally.

If you have been referred to an NHS fertility clinic with a PCOS diagnosis, that referral and any associated eligibility decision remains valid. You do not need to be rediagnosed.

What to Ask Your Fertility Consultant

Given the PMOS renaming, the following questions are worth raising at your next appointment:

  • Has my insulin resistance been formally assessed (fasting insulin + glucose tolerance test)?
  • Should I be on metformin or inositol before or during IVF?
  • What protocol do you recommend given my PMOS profile, and how will you manage OHSS risk?
  • Is there anything about my metabolic status that we should optimise before starting stimulation?
  • Given the PMOS framework, should I also be seen by an endocrinologist alongside the fertility team?

For a full pre-treatment question checklist, see 30 questions to ask your IVF consultant.

Frequently Asked Questions

Q: Do I need to tell my GP or clinic that PCOS has been renamed PMOS?

A: Not urgently — your diagnosis remains valid and the clinical criteria are unchanged. During the transition period (until approximately 2028), both terms will be in use. If you want to use the new terminology, you can — but it will not change your treatment plan immediately. What is more useful is asking whether your metabolic profile has been fully assessed, which is now explicitly part of the PMOS standard of care.

Q: I was told I don't have PCOS because my ultrasound didn't show polycystic ovaries. Should I be reassessed?

A: Possibly. The diagnostic criteria require two of three features — and polycystic ovarian morphology on ultrasound is only one of them. If you have irregular periods and evidence of elevated androgens, you may meet the diagnostic criteria without the ultrasound finding. The PMOS renaming specifically addresses the problem of patients being excluded from diagnosis because of overreliance on the "cyst" component. Raise this with your GP or a specialist.

Q: I have PMOS and I'm not trying to conceive. Does the renaming change my care?

A: Yes — this is one of the most significant practical implications of the rename. The PMOS framework explicitly states that metabolic and endocrine management is indicated regardless of fertility goals. If you have been told there is nothing to treat until you want children, the PMOS consensus directly contradicts that position. Ask your GP for a full metabolic review.

Q: Will NHS treatment for PMOS change because of the renaming?

A: Not immediately. NHS commissioning policies update on their own timescales. However, the clinical rationale for more comprehensive metabolic assessment is now explicitly supported by the international consensus. Individual consultants may update their practice sooner than formal NHS policy changes.

Q: Is PMOS the same condition as PCOS?

A: Yes — it is the same underlying condition, redefined to more accurately reflect what it is. No new condition has been discovered. The patients who had PCOS have PMOS; the biology has not changed, only the understanding and naming of it.

Information in this article is based on the global consensus published in The Lancet (May 2026) and does not constitute medical advice. Discuss any changes to your diagnosis or treatment with your GP or fertility specialist.